A study evaluating clinical outcomes of nintedanib plus docetaxel for refractory non small cell lung cancer patients: Retrospective analysis of korean nintedanib named patient usage program (KCSG LU14-2).

Trial Profile

A study evaluating clinical outcomes of nintedanib plus docetaxel for refractory non small cell lung cancer patients: Retrospective analysis of korean nintedanib named patient usage program (KCSG LU14-2).

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Docetaxel (Primary) ; Nintedanib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Jun 2017 New trial record
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top